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A B S T R A C T
Background: Vitamin D deficiency and polypharmacy is a common problem over chronic 
kidney disease (CKD) population.
Objectives: To assess the clinical and analytical characteristics of CKD patients with 25-OH-D3 
deficiency (<15 ng/mL), including the possible role of associated drugs.
Methods: A single center observational review of 137 incident patients referred to our outpatient 
clinic with different stages of CKD and 25-OH-D3<15ng/mL (male gender 53.3%, mean age 
70.8 [±16.1] years, mean GFR (MDRD-4) 43.6 [±25.5] ml/min/1.73 m2). 25-OH-D3 levels were 
collected in spring. Clinical and biochemical data and associated medications were recorded.
Results: Mean 25-OH-D3 levels were 8.23 [±4.03] ng/ml. Eighty-eight patients (64.7%) had 3 or 
more concomitant drugs. Only 7 patients (5.1%) were not receiving any medication. Patients 
were divided in three groups according the therapies into none (n=26), RAS inhibitors or 
allopurinol (n=81), and RAS inhibitors plus allopurinol (n=30); with the aim to study the 
influence of statin therapy. Patients under renin angiotensin (RAS) inhibitors or Allopurinol 
treatment presented significantly higher 25-OH-D3 levels (p=0.001 and p=0.01 respectively), 
however patients with Statins treatment had lower 25-OH-D3 level (p=0.039). Personal 
history of diabetes, cardiovascular events or other therapies did not modify 25-OH-D3 levels, 
adjusted by age and eGFR.
Conclusions: CKD patients with vitamin D deficiency who received RAS inhibitors or Allopurinol 
treatment had higher 25-OH-D3 levels, however those with statins treatment had lower 
vitamin D levels. Randomized controlled trials are required to confirm these findings.
© 2015 Sociedad Española de Nefrología. Published by ELSEVIER ESPAÑA, SLU. Published 
under the terms of the CC BY-NC-ND Licence(http://creativecommons.org/licenses/
by-nc-nd/4.0).
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Efectos de algunos fármacos administrados a los pacientes de ERC  
sobre los niveles de vitamina D
R E S U M E N
Antecedentes: La deficiencia de vitamina D y la polifarmacia constituyen un problema común 
en la población con enfermedad renal crónica (ERC).
Objetivos: Evaluar las características clínicas y analíticas de los pacientes de ERC con deficiencia 
de 25-OH-D3 (<15 ng/mL), incluyendo la función posible de los fármacos asociados.
Métodos: Se realizó una revisión observacional en un único centro, de 137 pacientes incidentes 
remitidos a nuestra clínica ambulatoria con diferentes estadios de ERC y 25-OH-D3<15 ng/mL 
(varones 53,3%, edad media 70,8 [±16,1] año, GFR medio (MDRD-4) 43,6 [±25,5] ml/min/1,73 m2). 
Los valores de 25-OH-D3 se recolectaron en primavera. Se registraron los datos bioquímicos 
y los fármacos asociados.
Resultados: Los niveles medios de 25-OH-D3 fueron de 8,23 [±4,03] ng/ml. Ochenta y ocho 
pacientes (64,7%) tomaban tres o más fármacos concomitantes. Únicamente siete pacientes 
(5,1%) no recibían medicación alguna. Los pacientes fueron divididos en tres grupos, conforme 
a las terapias: ninguna (n = 26), inhibidores RAS o Alopurinol (n = 81), e inhibidores RAS más 
alopurinol (n = 30), a fin de estudiar la influencia de la terapia de estatinas. Los pacientes 
sometidos a tratamiento de inhibidores de la renina-angiotensina (RAS) o Alopurinol presentaron 
unos niveles considerablemente superiores de 25-OH-D3 (p = 0,001 y p = 0,01 respectivamente), 
y sin embargo los pacientes con tratamiento de estatinas presentaron unos menores niveles 
de 25-OH-D3 (p = 0,039). La presencia de diabetes, episodios cardiovasculares u otras terapias 
no modificaron los niveles de 25-OH-D3, ajustados por edad y eGFR.
Conclusiones: Los pacientes de ERC con deficiencia de vitamina D, sometidos a tratamiento 
de inhibidores RAS o Alopurinol reflejaron unos niveles superiores de 25-OH-D3, y sin 
embargo aquellos sometidos a tratamiento de estatinas reflejaron unos menores niveles de 
vitamina D. Se precisan ensayos aleatorizados controlados para confirmar estos hallazgos.
© 2015 Sociedad Española de Nefrología. Publicado por ELSEVIER ESPAÑA, SLU. Publicado 
bajo los términos de la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0). 
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Introduction
Over last decade, interest in vitamin D physiopathology has 
increased greatly due to the discovery of additional biological 
actions of vitamin D out off its traditional role in bone and mine-
ral metabolism. These additional biological effects are: suppres-
sion of renin-angiotensin system1 (RAS), protection against 
cardiovascular event,2 decrease in inflammatory markers,3,4 
reduction of megalin and cubilin shedding,5 improved systolic 
blood pressure in patients with type 2 diabetes,6 and increases 
nephrin expression in podocytes in experimental data.7
On the other hand, vitamin D deficiency is an emerging 
global health problem that is estimated to affect more than 
1 billion people worldwide.8 It is very common in patients 
with chronic kidney disease (CKD), even at early stages,9 and 
the severity of deficiency increases with the progression of 
kidney disease.
Vitamin D deficiency is partly caused by vitamin dysregu-
lated D metabolism in kidney disease, because the final acti-
vation step of synthesis of Vitamin D, 1-hydroxylation, occurs 
primarily, but not exclusively, in the kidney.
CKD patients used to have a high comorbidity, so are trea-
ted with a huge amount of drugs.10,11 Therefore medication-
related problems are very common in CKD patients. The 
possible collateral effect of these medications on vitamin D 
synthesis and metabolism had been previously described,12,13 
but remains unclear.
We conducted an observational study to assess the cha-
racteristics of 25-OH-D3 deficient CKD patients, including the 
possible role of different associated therapies, as statins, 
renin angiotensin system (RAS) inhibitors or Allopurinol.
Methods
Participants
A transversal single-center study was conducted including 
a sample of 137 incident patients referred to our CKD outpa-
tient clinic. Patients undergoing renal replacement therapy, 
kidney transplant recipients, and with recent hospital 
admission in last 3 months or with acute diseases, were 
excluded. We also excluded patients supplemented with any 
kind of vitamin D or analog in the last 3 months. Medical 
records were consulted to obtain demographic, anthropo-
metric data and previous cardiovascular events. Treatment 
was also recorded: kind and number of antihypertensive 
drugs, statin and allopurinol therapy. Analytical values were 
collected at the same time including creatinine, calcium, 
phosphate, parathormone (PTH), serum uric acid, ultrasen-
sible C-reactive protein (CRP), proteinuria and urine albu-
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min/creatinine ratio. To avoid seasonal changes, serum 
25-OH-D3 levels were determined in all patients between 
February and May.
Patients were divided in three groups according RAS inhi-
bitors or allopurinol concomitant therapies into none (n=26), 
RAS inhibitors or allopurinol (n=81), and RAS inhibitors plus 
allopurinol (n=30); with the aim to study the influence of sta-
tin therapy in these groups.
Laboratory measurements were made using standardized 
automated methods. Daily urinary albumin excretion was 
measured with an immunonephelometric method. Serum 
25-OH-D3 levels and intact PTH were measured using stan-
darized automated methods of chemiluminescence immu-
noassay (Liaison® and Immulite 2000®, respectively).
Estimated glomerular filtration rate (eGFR) was calculated 
using the MDRD-4 formula.14 Vitamin D deficiency was defi-
ned according with KDOQI 2008 guidelines as 25-OH-D3 levels 
less than 15 ng/mL.15
Statistical analysis
Normally distributed values are expressed as mean ±SD 
(standard deviation); non-normally distributed values are 
expressed as median ±IQR (interquartile range). The diffe-
rences in quantitative variables were examined using the 
chi-square test for categorical variables and t test for conti-
nuous variables. Analysis of variance was used to study the 
differences on 25-OH-D3 levels between the groups accor-
ding concomitant therapies. A linear model was accomplis-
hed to identify the relationship between different variables. 
Multivariate analysis (linear multivariate regression) was 
performed to determine the independent risk factors for 
25-OH-D3 deficiency including all the factors with p<0.1 in 
the univariate model and potential confounding factors (as 
concomitant therapies, age, gender, diabetes mellitus, eGFR, 
and prior history of congestive cardiac failure). All statistical 
analyses were conducted using SPSS for Windows, V 11 
(SPSS®, Chicago, Illinois, USA). Statistical significance was 
set at P<0.05.
Results
Demographic data, clinical and baseline biochemical charac-
teristics are shown in Table 1. Mean serum 25-OH-D3 levels 
were 8.23±4.03 ng/ml. According with KDOQUI guidelines16 
86 patients (62.7%) had CKD stage 3, 10.2% stages 1 and 2, and 
27% presented eGFR<30 ml/min/1.73 m2. Although male gen-
der presented higher 25-OH-D3 levels (8.35 [±3.40] versus 7.52 
[±3.06] ng/dl) these differences are not significant. Sixty-one 
patients (33.2%) had a previous cardiovascular event (CVE). 
The most frequent was myocardial infarction with 14.7%. 
Previous congestive cardiac failure (CCF) had been found in 
18 patients (9.8%).
Eighty-eight patients (64.7%) were receiving 3 or more con-
comitant drugs. Only 7 patients (5.1%) were not receiving any 
treatment. Bone and mineral metabolism parameters and 
eGFR of the patients according concomitant medications are 
shown in Table 2. Patients under RAS inhibitors and allopu-
rinol treatment were associated with higher 25-OH-D3 levels. 
However, statin treatment, diabetes mellitus and history of 
CCF was associated with lower levels of 25-OH-D3 levels. 
Allopurinol-taking patients presented higher serum 
phosphate and PTH levels as well as and lower eGFR. Patients 
treated with insulin, erythropoiesis-stimulating agents (ESA) 
and with history of CVE presented lower eGFR. There are no 
differences between calcium levels according concomitant 
drugs. Multivariate analysis adjusted by age, gender, eGFR, 
serum calcium and PTH levels, personal history of diabetes, 
Table 1 – Baseline characteristic of the patients
Baseline characteristic
Characteristic Total Statin therapy
Yes No P value
n=137 N=74 n=63
Male Gender (%) 53.3% 49.3% 50.7% 0.24*
Hypertension (Yes) (%) 91.9% 54.4% 45.6% 0.77*
Diabetes Mellitus (Yes) (%) 40.9% 69.6% 30.45 0.003*
Age (years) 70.77 (±16.1) 72.7 (±13.1) 68.5 (±19.9) 0.12
eGFR (MDRD-4) (ml/min/1.73m²) 43.62 (±26.22) 39.5 (±18.9) 48.5 (±32.3) 0.53
Serum 25-OH-D3 levels (ng/mL) 8.23 (±4.03) 7.38 (±2.9) 8.66 (±3.6) 0.022
Serum Calcium levels (mg/dL) 9.1 (±0.53) 9.14 (±0.52) 9.09 (±0.52) 0.62
Serum phosphate levels (mg/dL) 3.54 (±0.68) 3.6 (±0.71) 3.5 (±0.65) 0.64
Serum PTH levels (ng/L) 200.5 (±230.8) 175.8 (±129.4) 222.7 (±290.9) 0.22
Serum uric acid levels (mg/dL) 6.84 (±1.77) 6.76 (±1.77) 6.92 (±1.76) 0.59
Serum CRP (mg/L) 0.61 (±0.92) 0.59 (±0.92) 0.62 (±0.94) 0.86
Urine Albumin/Creatinine ratio (mg/g) 564.0 (±994.6) 586.7 (±898.2) 542.0 (±1097.4) 0.85
eGFR, estimated glomerular filtration rate; CRP, C-reactive protein, PTH, parathyroid hormone. 
P-value obtained by T-student test, except * obtained by Mann- Whitney test. 
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Table 2 – Analytical characteristic of the patients according with the therapies
n 25-OH-D3 (ng/L) p Phosphate (ng/L) p Calcium (mg/dL) p PTH (mg/dL) p eGFR MDRD-4 (ml/
min/1.73m²)
p
Therapy 
RAS inhibitors  
(yes/no) 
113/ 
34
8.61 [3.95]/ 
6.70 [2.50]
.001 3.57 [.71]/ 
3.44 [.59]
.33 9.14 [.54]/ 
9.04 [.48]
.32 147 [108-222]/ 
213 [117-304]
.75* 41.7 [24.1]/ 
49.5 [31.5]
.138
Allopurinol  
(yes/no)
38/ 
99
9.78 [4.67]/ 
7.62 [3.19] 
.01 3.74 [.73]/ 
3.46 [.65]
.03 9.20 [.47]/ 
9.09 [.55]
.22 189 [126-307]/ 
147 [100-215]
.004* 35.0 [11.1]/ 
46.9 [29.4]
.001
Statins  
(yes/no)
74/ 
63
7.55 [3.31]/ 
8.83 [4.08] 
.039 3.57 [.07]/ 
3.51 [.65]
.64 9.14 [.52]/ 
9.10[.54]
.62 166 [121-253]/ 
144 [98, 219]
.12* 39.5 [18.9]/ 
48.5 [32.3]
.056
Omega-3  
(yes/no)
5/ 
131
6.2 [5, 11.5]/ 
7.6 [4.9, 10.4] 
.97* 3.41 [2.51-4.05]/ 
3.46 [3.03-4.02]
.58* 9.2 [8.75- 9.6]/ 
9.2 [8.8-9.4]
.65* 135 [77-189]/ 
150 [109-241]
.43* 43.1 [35.8-86]/ 
36.8 [35.7-48]
.19*
OAD  
(yes/no)
24/ 
113
6.5 [4, 11.1]/ 
7.55 [4.9, 10.4]
.108 3.62 [.68]/ 
3.54 [.68]
.46 9.15 [.53]/ 
9.11 [.53]
.75 156 [98-245]/ 
150 [110-239]
.85* 43.5 [24.5]/ 
43.7 [26.7]
.98
Insulin  
(yes/no)
23/ 
114
7.21 [3.04]/ 
8.44 [4.18] 
.18 3.57 [.70]/ 
3.50 [.68]
0.82 9.17 [.43]/ 
9.11 [.55]
.61 183 [113-242]/ 
150 [107-238]
.47* 36.2 [10.1]/ 
45.2 [28.2]
.009
OAD + Insulin  
(yes/no)
7/ 
130
6.5 [4, 11.1]/ 
7.55 [4.9, 10.4]
.58* 3.52 [3-4.2]/ 
3.43 [3-4]
.89* 9.3 [9-9.6]/ 
9.2 [8.8-9.4]
.34* 126 [121-150]/ 
153 [107-242]
.52* 37.1 [29.3-48.2]/ 
38.5 [25.7-39.4]
.66*
Aspirin  
(yes/no)
29/ 
103
8.51 [3.53]/ 
7.98 [ 3.74]
.49 3.42 [.72]/ 
3.57 [.67]
.28 9.14 [.43]/ 
9.11 [.55]
.76 189 [135-260]/ 
146 [101-221]
.72* 37.9 [11.1]/ 
45.2 [28.8]
.038
ESA  
(yes/no)
11/ 
125
6.42 [2.67]/ 
8.28 [3.74]
.17* 3.91 [3.24-4.41]/ 
3.42 [3.0-4.0]
.09* 9.12 [8.71-9.53]/ 
9.22 [8.86-9.43]
.55* 150 [105-336]/ 
229 [111-225]
.28* 25.1 [21.6-33.6]/ 
38.6 [30.1-49.1]
.001*
Past medical history 
Gender  
(male/female)
73/ 
64
8.35 [3.40]/ 
7.52 [3.06]
.13 3.44 [0.69]/ 
3.71 [0.65]
.03 9.0 [0.52]/ 
9.2 [052]
.14 146 [96-226]/ 
165 [119-260]
.10* 47.0 [29.2]/ 
39.8 [21.8]
.11
Diabetes  
(yes/no)
81/ 
56
7.14 [2.95]/ 
8.88 [4.06]
.005 3.52 [0.68]/ 
3.65 [0.69]
.68 9.1 [0.56]/ 
9.2 [0.47]
.24 154 [121-220]/ 
148 [101-244]
.69 39.5 [18.3]/ 
46.5 [30.3]
.09
History of CCF  
(yes/no)
19/ 
129
6 [4.5-8.25]/ 
7.7 [4.98-10.5]
.004* 3.54 [0.65]/ 
3.53 [0.69]
.96* 9.13 [0.53]/ 
9.11 [0.53]
.87* 221 [128-277]/ 
148 [104-222]
.09* 39.4 [28.8-45.7]/ 
36.7 [28.7-48.8]
.92*
History of CVE  
(yes/no)
60/ 
77
7.45 [4.93-9.93]/ 
7.7 [4.8-10.55]
.5* 3.47 [0.66]/ 
3.59 [0.7]
.34 9.08 [0.50]/ 
9.16 [0.56]
.47 187 [134-279]/ 
132 [91-213]
.001* 36.6 [11.3]/ 
49.1 [32.6]
.002
Proteinuria  
(yes/no)
34/ 
100
7.16 [3.24]/ 
8.3 [3.28]
0.075 3.60 [0.75]/ 
3.51 [0.67]
.49 8.97 [0.54]/ 
9.18 [0.52]
.52 146 [101-189]/ 
154 [114-253]
.38* 41.0 [21.4]/ 
445 [127.8]
.38
n, number of patients; eGFR, estimated glomerular filtration rate; RAS inhibitors, inhibitors of renin-angiotensin-aldosterone system; CCF, congestive cardiac failure; OAD, oral antidiabetic 
drugs; ESA, erythropoiesis-stimulating agents. Proteinuria yes if Urine Albumin Creatinine ratio >300 mg/g.
P-value obtained by T-student test, except * obtained by Mann- Whitney test.
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CVE or CCF showed that RAS inhibitors (beta 1.73, p=0.013), 
allopurinol treatment (beta 1.63, p=0.011) and statins 
treatment (beta –1.35 and p=0.029) were independent predic-
tors for lower serum 25-OH-D3 levels (Table 3).
Patients who were not receiving RAS inhibitors or allo-
purinol presented lower 25-OH-D3 levels than those 
receiving RAS inhibitors or allopurinol, and RAS inhibitors 
plus allopurinol (p<0.001) (Fig. 1). Highest 25-OH-D3 levels 
(11.7±3.11 ng/mL) of our cohort were found in patients 
receiving RAS inhibitors plus allopurinol without statins. 
Lowest 25-OH-D3 levels of our cohort (5.7±1.82 ng/mL) 
were found in patients who receiving statins alone. In the 
group without RAS inhibitors or Allopurinol patients under 
statins therapy presented lower serum vitamin D levels 
(5.7±1.82 ng/mL vs. 7.8±3.4 ng/mL, p=0.05) compared with 
patient under RAS inhibitors or Allopurinol alone. Similarly, 
in the group with RAS inhibitors plus Allopurinol patients 
under statins therapy presented lower serum vitamin D 
levels (11.7±3.5 ng/mL vs. 8.5±2.5 ng/mL, p=0.003) than 
those with RAS inhibitors plus Allopurinol alone. There 
were also statistical differences when we compared 
patients under statin treatment with and without RAS or 
allopurinol therapy (5.7±1.82 ng/mL vs. 7.5±3.2 ng/mL, 
respectively p=0.015) and comparing patients under statin 
treatment with RAS or allopurinol therapy with patients 
under RAS plus allopurinol therapy (5.7±1.82 ng/mL vs. 
8.5±2.3 ng/mL, p=0.02 respectively). Similarly, there were 
statistical differences comparing patients without statin 
treatment with RAS inhibitors or Allopurinol treatment 
vs. RAS inhibitors plus Allopurinol (7.8±3.4 ng/mL vs. 
11.7±3.5 ng/mL, p=0.002).
Additionally, we collected 25-OH-D3 levels in 23 CKD 
patients before (17.8 [11.9-26.45]) and 3 months after (22.0 
[13.65-27.45]) RAS inhibitors introduction (p<0.001), and in 
15 patients before (43.3 [14.0-76.8]) and 3 months after (25.7 
[23.2-43.3]) Allopurinol introduction (p=0.66).
Discussion
Our data suggest that concomitant treatment with allopurinol 
and RAS inhibitors is associated with high levels of 25-OH-D3 
in CKD vitamin D deficient population. On the other hand, 
treatment with statins is associated with lower levels.
CKD patients used to have a high comorbidity and there-
fore are treated with a huge amount of drugs. The possible 
collateral effect of these medications on vitamin D synthesis 
and metabolism had been previously described in some 
reports, but remains unclear.
Although the interaction between Vitamin D and RAS is 
well known there are not previous reports about the effect of 
RAS inhibition on vitamin D levels. Vitamin D is a down regu-
lator of the RAS by supressing renin expression,1,17 and its 
deficiency can activate the local RAS in the kidney.18 The 
renoprotective and antiatherogenic efficacy of the combina-
tion therapies of RAS inhibitors and vitamin D analogue has 
been reported in animal models.19-21 To provide biological 
plausibility to our finding, we have 2 different arguments. 
Firstly, RAS inhibitors by decreasing glomerular proteinuria, 
decrease the competition between proteins and vitamin D for 
receptor-binding site to be reabsorbed by megalin-cubilin 
complex in the proximal tubule.22 That means that RAS inhi-
bitors increase the free receptor-binding sites for vitamin D 
reabsorption. And secondly, RAS inhibitors have a potent anti-
inflammatory effect23,24 and the inflammatory status has 
been associated in many studies with vitamin D levels.3-5
Patients treated with Allopurinol had higher 25-OH-D3 
levels. We did not find any association with serum uric acid 
levels. Takahashi et al. described a lower serum 1-25 (OH) D3 
levels in gout patients compared with control subjects, and a 
significant increase in serum 1-25 (OH) D3 after 1 year of 
Table 3 – Linear Multivariate Regression (adjusted by 
age, eGFR and prior history of Congestive cardiac failure)
P value Beta
Allopurinol treatment p=0.011 1.63
RAS inhibitors p=0.013 1.73
Statin Treatment p=0.029 –1.35
Diabetes Mellitus p=0.06 –1.18
RAS inhibitors, inhibitors of renin-angiotensin-aldosterone system.
Figure 1 – Relationship between therapies and baseline 
serum 25-OH-D3 levels. Patients were divided in three 
groups according with the concomitant therapies, and 
there were significant statistical differences between 
groups (p<0.001). Patients who were not receiving renin 
angiotensin system (RAS) inhibitors or allopurinol (n=26) 
presented lower 25-OH-D3 D levels than those receiving 
RAS inhibitors or allopurinol (n=81), and RAS inhibitors 
plus allopurinol (n=30) (p<0.001). Highest 25-OH-D3 levels 
(11.7±3.11, p=0.003) were found in patients receiving 
RAS inhibitors plus allopurinol without statins. Lowest 
25-OH-D3 levels (5.7±1.82, p=0.005) were found in patients 
who only receiving statins.
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